Condition
Medical Oncology
Estimated Enrollment: 30
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: 17631
Study First Received: November 30, 2015
Last Updated: April 12, 2017
Estimated Primary Completion Date: March 26, 2018
Primary Outcome Measures:
Maximum tolerated dose (MTD)|Number of subjects with adverse events and serious adverse events as a measure of safety and tolerability|Plasma concentrations of anetumab ravtansine (BAY 94-9343), pemetrexed and cisplatin|Tumor response evaluation following mRECIST criteria to determine the number of patients with CR, PR, SD or PD|Number of patients with a positive titer of anti-drug antibodies
Sponsors and Collaborators:
Bayer
Website Link: https://ClinicalTrials.gov/show/NCT02639091
